Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-5500 + docetaxel
- Development stage
- Unknown
- Lead developer
- Vir Biotechnology
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
VIR-5500 + docetaxel is an investigational combination regimen being evaluated for the treatment of advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). VIR-5500 (formerly AMX-500 or SAR446329) is a dual-masked, prostate-specific membrane antigen (PSMA)-targeted bispecific T-cell engager (TCE). It binds to PSMA on prostate cancer cells and CD3 on T cells, directing cytotoxic T-cell activity against the tumor. It incorporates the proprietary PRO-XTEN protease-cleavable masking technology, which is designed to keep the molecule inactive in systemic circulation and selectively activate it within the tumor microenvironment, minimizing off-tumor toxicities such as cytokine release syndrome. Docetaxel is a well-established taxane chemotherapy that binds to and stabilizes microtubules, preventing their depolymerization and disrupting mitosis. The combination is being co-developed by Vir Biotechnology and Astellas Pharma and is currently undergoing Phase 1 clinical evaluation.
- Other names
- AMX-500 + docetaxelAMX-500 + TaxotereSAR446329 + docetaxelSAR446329 + TaxotereVIR-5500 + Taxotere
02
Targets
PSMA (Prostate-specific membrane antigen)CD3 (T-cell surface glycoprotein CD3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on VIR-5500 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-5500 + docetaxel.